Recent Scientific Publications

Association of Vascular Risk Factors and Cerebrovascular Pathology with Alzheimer Disease Pathologic Changes in Individuals Without Dementia 

  • Date October 8th  2024
  • Presentation type: co-authored journal manuscript with the AMYPAD consortium in the journal Neurology
  • Synopsis: investigation of links between vascular risk factors, cerebral small vessel disease, and amyloid levels and their combined effect on downstream AD biomarkers.
  • Therapeutic Indication: Alzheimer’s disease (AD)

 

A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial.

  • Date: October 31st 2024
  • Presentation type: oral presentation at the 17th Clinical Trials in Alzheimer’s Disease (CTAD) conference in Madrid, Spain.
  • Synopsis: analysis of the Global Alzheimer’s Platform Bio-Hermes data to investigate how blood-based-biomarkers can be operationalised in conjunction with PET imaging.
  • Therapeutic Indication: Alzheimer’s disease (AD)

Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study

  • Date: January 2025
  • Presentation type: co-authored journal manuscript with the AMYPAD consortium in The Journal of Nuclear Medicine
  • Synopsis: analysis of the AMYPAD study data that shows how automated quantitative analysis of amyloid PET data can support and streamline visual expert assessment.
  • Therapeutic Indication: Alzheimer’s disease (AD)

Comparison of two natural history studies as part of the HD-IH consortium: a use case for historical external control group matching in clinical trials

  • Date: 25th February 2025
  • Presentation type: poster presentation at the 20th Annual HD Therapeutics Conference in Palm Springs, CA.
  • Synopsis: analysis of data from the HD-IH consortium to show that external control groups can support regulatory decision-making in clinical trials, especially rare diseases like Huntington’s disease (HD).
  • Therapeutic Indication: Huntington’s disease (HD)

The Potential of Blood-Based Biomarkers & Digital Assessments in Transforming Research and Clinical Practice

  • Date: February 26th 2025
  • Presentation type: invited podium presentation and discussion at the GAP-Net Site Optimization Conference 2025
  • Synopsis: invited presentation to discuss the critical role of imaging in an evolving AD biomarker landscape, specifically in combination with novel blood based biomarker tests. Joint panel with C-level experts from diagnostics and pharma companies.
  • Therapeutic Indication: Alzheimer’s disease (AD)

Neuroimaging Biomarkers for Friedreich Ataxia: A Cross-Sectional Analysis of the TRACK-FA Study

  • Date: March 22nd 2025
  • Presentation type: co-authored journal manuscript with the TRACK-FA consortium in the Annals of Neurology Journal
  • Synopsis: development and validation of novel brain and spinal cord volumetric biomarkers for Friedreich’s Ataxia as part of the TRACK-FA study.
  • Therapeutic Indication: Friedreich’s Ataxia (FA)

AI-Driven Classification of Alzheimer’s Disease and Frontotemporal Dementia from Magnetic Resonance Imaging

  • Date: April 4th 2025
  • Presentation type: oral presentation at the 40th International Conference on Alzheimer’s Disease and Parkinson’s Disease (ADPD) in Vienna, Austria
  • Synopsis: development and validation of novel AI-driven measurements to support differential diagnosis between AD and FTD from volumetric MRI.
  • Therapeutic Indication: Alzheimer’s disease (AD); Frontotemporal dementia (FTD)

Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis

  • Date: April 17th 2025
  • Presentation type: invited editorial in the Journal for Clinical Studies
  • Synopsis: editorial discussion on the multimodal use of PET imaging in combination with novel blood based biomarkers to support streamlined clinical trial delivery.
  • Therapeutic Indication: Alzheimer’s disease (AD)

AI-Driven Recruitment for Alzheimer’s Disease Clinical Trials: A Pilot Analysis on the A4 Dataset

  • Date: 28th July 2025
  • Presentation type: poster presentation at the Alzheimer’s Association International Conference 2025 in Toronto, Canada
  • Synopsis: embargoed
  • Therapeutic Indication: Alzheimer’s disease (AD)